Kolexia
Rivera Pascale Oncologie médicale
Rivera Pascale
Oncologie médicale
Hôpital Rangueil
Toulouse, France
34 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du foie Tumeurs colorectales Carcinomes Épithélioma in situ Adénocarcinome {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Guimbaud Rosine
Guimbaud Rosine
Hôpital Rangueil, Toulouse, France
Deslandres-Cruchant Marion
Deslandres-Cruchant Marion
Hôpital Purpan, Toulouse, France
Couteau Corinne
Couteau Corinne
Centre Hospitalier de Albi, Albi, France
Fares Nadim
Fares Nadim
Hôpital Rangueil, Toulouse, France

Industries

Voir plus
Servier
10 collaboration(s)
Dernière en 2023
MSD
2 collaboration(s)
Dernière en 2023
B3TSI
2 collaboration(s)
Dernière en 2021
MundiPharma
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
BACAP-2: Anatomical-Clinical Base of Adenocarcinoma Pancreatic
Essai Clinique (CHU Toulouse)   20 novembre 2023
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Clinical breast cancer   20 juin 2023
Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer.
Frontiers in medicine   16 juin 2022
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years: An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab
Essai Clinique (Roche)   03 septembre 2020
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
European journal of cancer (Oxford, England : 1990)   23 juin 2017
Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
Standardization of the geriatric assessment within the Midi-Pyrenees Unite de Coordination in Oncogeriatrie
Geriatric Oncology: Cancer in Senior Adults - Abstracts of the 13th Meeting of the International Society of Geriatric Oncology   01 octobre 2013
Completeness and quality of multidisciplinary team meetings: the example of breast cancer in Tarn.
Bulletin du cancer   26 novembre 2012
Hepatic Arterial Infusion (HAI) of Oxaliplatin Plus Intravenous (IV) Fluorouracil (FU), Leucovorin (LV) and Cetuximab for First-Line Treatment of Unresectable Colorectal Liver Metastases (CRLM): Final Results of a Multicenter Phase 2 Study (CHOICE)
Abstract Book of the 37th ESMO Congress Vienna, Austria, 28 September - 2 October 2012   01 septembre 2012